CLGN

CollPlant Biotechnologies Ltd. (NASDAQ:CLGN) is an Israeli biotechnology company founded in 2004 and headquartered in Rehovot, Israel. The company went public on NASDAQ in January 2018. CollPlant specializes in regenerative and aesthetic medicine, focusing on developing innovative medical products based on recombinant human collagen produced through proprietary plant-based genetic engineering technology. The company operates in the rapidly evolving biotechnology sector, developing solutions for tissue regeneration, wound care, and aesthetic medicine applications.